<DOC>
	<DOCNO>NCT01725529</DOCNO>
	<brief_summary>The purpose study provide confirmatory efficacy safety data TMC435 part treatment regimen include peginterferon-alpha ( PegIFNα-2a ) ribavirin ( RBV ) patient genotype 1 Hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>An Efficacy , Pharmacokinetics , Safety Tolerability Study TMC435 Part Treatment Regimen Hepatitis C-Infected Patients</brief_title>
	<detailed_description>This multicenter , randomize ( study drug assign chance ) , double-blind ( neither sponsor , physician patient know name assign study drug ) , Phase III study compare efficacy , tolerability safety TMC435 ( development treatment chronic hepatitis C virus [ HCV ] infection ) versus placebo ( preparation contain drug use control ) part treatment regimen include peginterferon-alpha ( PegIFNα-2a ) ribavirin ( RBV ) ( current therapy HCV ) adult treatment-naïve patient ( patient never take HCV medication ) genotype 1 Hepatitis C virus ( HCV ) infection . The study consist screen period maximum duration 6 week , response guide 24- 48-week ( TMC435 treatment group ) 48-week ( control group ) treatment period , post-therapy follow-up period 72 week start treatment . Patients randomly assign 1:1:1 fashion receive TMC435 placebo , stratify HCV genotype 1 subtype IL28B genotype within country . In first 24 week , patient receive 12 week TMC435 100 150 mg placebo once-daily ( q.d . ) plus PegIFNα-2a plus RBV , continue PegIFNα-2a RBV . Response-guided treatment criterion use determine PegIFNα-2a RBV total treatment duration 24 48 week patient TMC435 treatment group . In control group , patient require complete 48 week treatment PegIFNα-2a RBV . In 3 treatment group , post-therapy follow-up period 72 week start treatment . The total study duration patient maximum 78 week ( include 6-week screening period ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>A liver biopsy within 3 year prior screen visit ( screen day randomization ) histology consistent chronic Hepatitis C virus ( HCV ) infection Presence contraindication liver biopsy patient otherwise deem eligible participation exclude patient participation Genotype 1 HCV infection ( confirmed screening ) Plasma HCV RNA &gt; 10,000 IU/mL screen Prior treatment approve investigational drug treatment hepatitis C Coinfection hepatitis B virus human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>TMC435</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>peginterferon-alpha ( PegIFNα-2a )</keyword>
</DOC>